Amvona - Congress

Menu:

Investors Sue Ligand Pharmaceuticals (NASDAQ: LGND) for $3.8 Billion

Subscribe to this RSS feed

Amvona publishes critical articles and interviews at the intersection of Faith, Finance and Economics.

Tweets

Wed Aug 10 01:32:30 +0000 2022

In '14 @Lemelson called for the ouster of @VinceMcMahon amid what he called "material misstatements" $WWE now says… https://t.co/UaSMrme7Z1

Fri Jul 22 20:57:52 +0000 2022

.@VinceMcMahon "Retires" As Chief of $WWE Amid Ongoing Probe Into Alleged Misconduct. In '14 @Lemelson called for… https://t.co/vQ3qPaoPB6

Wed Jul 06 16:03:47 +0000 2022

.@Lemelson will join Lemelson Capital Management on the Q2 2022 investor call on July 15. The call will include pr… https://t.co/cJVUYnPuiO

Thu Feb 10 21:46:30 +0000 2022

RT @LemelsonCapital: .@LemelsonCapital Reports Preliminary January 22 Results January 2022 net returns of 49.12 percent "We concluded Jan…

Fri Jan 14 13:24:08 +0000 2022

RT @LemelsonCapital: .@LemelsonCapital Reports Preliminary FYE 21 Results FYE 21 combined net returns of 56%. Est. MTD Jan. 22 net return…

145 Pine Haven Shores Road
Suite 2293
Shelburne, VT 05482

Feel free to email us. We would be happy to answer any questions you might have.